A decade of investments in monitoring the HIV epidemic: how far have we come? A descriptive analysis

被引:4
|
作者
Alfven, Tobias [1 ]
McDougal, Lotus [2 ]
Frescura, Luisa [1 ]
Aran, Christian [1 ]
Amler, Paul [3 ]
Gill, Wayne [4 ]
机构
[1] UNAIDS, Strateg Informat & Monitoring Div, CH-1211 Geneva, Switzerland
[2] Univ Calif San Diego, La Jolla, CA 92093 USA
[3] Univ Technol Berlin, Berlin, Germany
[4] Soul Syst, Strateg Informat, Georgetown, ON, Canada
来源
关键词
AIDS spending; United Nations General Assembly Special Session on HIV/AIDS (UNGASS); HIV; Monitoring and evaluation; National Composite Policy Index; SYSTEMS; HEALTH;
D O I
10.1186/1478-4505-12-62
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: The 2001 Declaration of Commitment (DoC) adopted by the General Assembly Special Session on HIV/AIDS (UNGASS) included a call to monitor national responses to the HIV epidemic. Since the DoC, efforts and investments have been made globally to strengthen countries' HIV monitoring and evaluation (M&E) capacity. This analysis aims to quantify HIV M&E investments, commitments, capacity, and performance during the last decade in order to assess the success and challenges of national and global HIV M&E systems. Methods: M&E spending and performance was assessed using data from UNGASS country progress reports. The National Composite Policy Index (NCPI) was used to measure government commitment, government engagement, partner/civil society engagement, and data generation, as well as to generate a composite HIV M&E System Capacity Index (MESCI) score. Analyses were restricted to low and middle income countries (LMICs) who submitted NCPI reports in 2006, 2008, and 2010 (n = 78). Results: Government commitment to HIV M&E increased considerably between 2006 and 2008 but decreased between 2008 and 2010. The percentage of total AIDS spending allocated to HIV M&E increased from 1.1% to 1.4%, between 2007 and 2010, in high-burden LMICs. Partner/civil society engagement and data generation capacity improved between 2006 and 2010 in the high-burden countries. The HIV MESCI increased from 2006 to 2008 in high-burden countries (78% to 94%), as well as in other LMICs (70% to 77%), and remained relatively stable in 2010 (91% in high-burden countries, 79% in other LMICs). Among high-burden countries, M&E system performance increased from 52% in 2006 to 89% in 2010. Conclusions: The last decade has seen increased commitments and spending on HIV M&E, as well as improved M&E capacity and more available data on the HIV epidemic in both high-burden and other LMICs. However, challenges remain in the global M&E of the AIDS epidemic as we approach the 2015 Millennium Development Goal targets.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Milestones in Heart Failure: How Far We Have Come and How Far We Have Left to Go
    Gajjela, Harini
    Kela, Iljena
    Kakarala, Chandra L.
    Hassan, Mohammad
    Belavadi, Rishab
    Gudigopuram, Sri Vallabh Reddy
    Raguthu, Ciri C.
    Modi, Srimy
    Sange, Ibrahim
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (12)
  • [32] Electronic health records: How far have we come? How far do we have to go?
    Waegemann, CP
    TOWARD AN ELECTRONIC HEALTH RECORD EUROPE '97 - CONFERENCE ON THE CREATION OF A EUROPEAN ELECTRONIC HEALTH RECORD, CONFERENCE PROCEEDINGS, 1997, : 8 - 10
  • [33] DIVERSITY AND INCLUSION: HOW FAR HAVE WE COME? HOW FAR CAN WE GO?
    Pennington, Greg
    CONSULTING PSYCHOLOGY JOURNAL-PRACTICE AND RESEARCH, 2020, 72 (04) : 324 - 331
  • [34] Tracheobronchomalacia treatment: how far have we come?
    Lopez-Padilla, Daniel
    Garcia-Lujan, Ricardo
    Puente Maestu, Luis
    de Miguel Poch, Eduardo
    JOURNAL OF THORACIC DISEASE, 2016, 8 (12) : 3490 - 3493
  • [35] Cardiopulmonary Resuscitation How Far Have We Come?
    Whitcomb, John J.
    Blackman, Virginia Schmied
    DIMENSIONS OF CRITICAL CARE NURSING, 2007, 26 (01) : 1 - 6
  • [36] In vitro oogenesis: How far have we come?
    Arkoun, B.
    Livera, G.
    GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE, 2018, 46 (01): : 41 - 46
  • [37] Immunotherapy in myeloma: how far have we come?
    Franssen, Laurens E.
    Mutis, Tuna
    Lokhorst, Henk M.
    van de Donk, Niels W. C. J.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2019, 10 : 1 - 19
  • [38] Cardiac Retransplantation: How Far Have We Come?
    Pandya, K.
    Lyons, K.
    Nsair, A.
    Baas, A.
    Cadeiras, M.
    Cruz, D.
    Reardon, L.
    Deng, M.
    Ardehali, A.
    Depasquale, E.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2015, 34 (04): : S170 - S170
  • [39] Microbial proteomics: how far have we come?
    Cordwell, Stuart J.
    MICROBIOLOGY AUSTRALIA, 2011, 32 (04) : 169 - 173
  • [40] Chemical cordotomy ... how far have we come?
    Pawl, Ron
    SURGICAL NEUROLOGY, 2008, 70 (06): : 599 - 599